

March 10, 2026

Company name: Nichiban Co., Ltd.
Name of representative: Toshiaki Takatsu, President
(Securities code: 4218 TSE Prime)
Inquiries: Yuko Kobayashi, Operating Officer,
General Manager of Corporate
Communication Department
(Telephone: +81-3-6386-7190)

Notice Regarding the Financial Results of Parent Company, etc.

Nichiban Co., Ltd. (the “Company”) hereby announces the financial results of TAIHO PHARMACEUTICAL CO., LTD., the Company’s parent company, etc., for the fiscal year ended December 31, 2025, as described below.

1. Name, etc. of the parent company, etc.

- (1) Name: TAIHO PHARMACEUTICAL CO., LTD.
- (2) Location: 1-27 Kandanshiki-cho, Chiyoda-ku, Tokyo, Japan
- (3) Title and name of representative: Masayuki Kobayashi, President and Representative Director
- (4) Business description: Manufacture and sale of pharmaceuticals
- (5) Share capital : 200 million yen
- (6) Attribute: Classified as other associated company (meaning the other company in cases where the Company is an affiliated company of the other company)
- (7) Relationship with the Company
 - (i) Capital relationship: Percentage of voting rights, etc. held: 33.22%
(as of September 30, 2025)
 - (ii) Personnel relationship: As of December 31, 2025, there are no personnel relationships to be stated.
 - (iii) Business relationship: Sale of products and purchase of merchandise

2. Shareholdings of the parent company by shareholder type, major shareholders, and Directors and Audit & Supervisory Board Members

(1) Shareholdings by shareholder type

As of December 31, 2025

Category	Status of shares								Status of shares less than one unit (Shares)
	Central and local governments	Financial institutions	Financial instruments business operators	Other corporations	Foreign corporations, etc.		Individuals, and others	Total	
					Non-individuals	Individuals			
Number of shareholders (Persons)	—	—	—	1	—	—	—	1	—
Number of shares held (Shares)	—	—	—	400,000	—	—	—	400,000	—
Percentage of shares held (%)	—	—	—	100.0	—	—	—	100.0	—

(2) Major shareholders

As of December 31, 2025

Name	Address	Number of shares held (Shares)	Proportion of number of shares held to total number of issued shares (%)
Otsuka Holdings Co., Ltd.	2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo	400,000	100.0
Total	—	400,000	100.0

(3) Directors and Audit & Supervisory Board Members

As of December 31, 2025

Position	Name	Areas of responsibility and significant concurrent positions outside the Company
President and Representative Director	Masayuki Kobayashi	Senior Executive Director and Board Member of Otsuka Holdings Co., Ltd.
Managing Director	Atsushi Azuma	In charge of Human Resources Division, Intellectual Property Department, Legal Affairs Department, Compliance Department (Corporate Management and Administration Division), Quality and Reliability Assurance Division, Business Development Department, and Finance and Accounting Department
Managing Director	Tatsuya Niki	In charge of Pharmaceutical Technology Division and General Affairs Division
Executive Director	Takeshi Sagara	In charge of Clinical Development & Medical Affairs Division and Discovery and Preclinical Research Division
Executive Director	Noriyuki Takahashi	In charge of Corporate Planning Department, Digital and IT Department, and Ethical Drug Sales and Marketing Division
Standing Audit & Supervisory Board Member	Nobuyuki Hashimoto	
Standing Audit & Supervisory Board Member	Yasunori Okada	
Audit & Supervisory Board Member	Tatsuya Nakajima	

(Note) Audit & Supervisory Board Member Tatsuya Nakajima is an outside Audit & Supervisory Board Member.

3. Financial statements of parent company, etc.

Balance Sheet

(As of December 31, 2025)

(Millions of yen)

Account items	Amount	Account items	Amount
Assets		Liabilities	
Current assets	221,182	Current liabilities	46,016
Cash and deposits	54,967	Accounts payable - trade	5,298
Notes receivable - trade	1,469	Accounts payable - other	30,865
Accounts receivable - trade	107,019	Income taxes payable	2,066
Merchandise and finished goods	16,408	Accrued consumption taxes	509
Work in process	9,506	Contract liabilities	2,647
Raw materials and supplies	14,171	Deposits received	3,580
Deposits paid to subsidiaries and associates	12,559	Provision for bonuses	1,048
Other	5,080	Non-current liabilities	12,898
Non-current assets	254,882	Long-term accounts payable - other	308
Property, plant and equipment	43,974	Long-term contract liabilities	806
Buildings	19,029	Asset retirement obligations	526
Structures	1,612	Provision for bonuses	299
Machinery and equipment	4,383	Long-term borrowings from subsidiaries and associates	10,957
Vehicles	34	Total liabilities	58,915
Tools, furniture and fixtures	3,421	Net assets	
Land	14,391	Shareholders' equity	412,194
Construction in progress	1,101	Share capital	200
Intangible assets	2,604	Capital surplus	15
Commercialization rights	1,090	Legal capital surplus	15
Software	1,310	Retained earnings	411,979
Telephone subscription right	5	Legal retained earnings	50
Other	198	Other retained earnings	411,929
Investments and other assets	208,303	Reserve for research and development	250,000
Investment securities	22,316	General reserve	128,300
Shares of subsidiaries and associates	157,930	Reserve for acquisition of specific shares	70
Investments in capital of subsidiaries and associates	1,411	Retained earnings brought forward	33,558
Long-term prepaid expenses	365	Valuation and translation adjustments	4,954
Prepaid pension costs	11,236	Valuation difference on available-for-sale securities	4,954
Deferred tax assets	13,226	Total net assets	417,149
Guarantee deposits	1,784	Total liabilities and net assets	476,064
Other	60		
Allowance for doubtful accounts	(28)		
Total assets	476,064		

Statements of Income

(from January 1, 2025 to December 31, 2025)

(Millions of yen)

Account items	Amount	
Net sales		215,621
Cost of sales		42,981
Gross profit		172,639
Selling, general and administrative expenses		127,854
Operating profit		44,785
Non-operating income		
Income related to investments in investment partnerships	629	
Interest and dividend income	686	
Rent income	175	
Other	141	1,632
Non-operating expenses		
Interest expenses	939	
Foreign exchange losses	709	
Other	10	1,659
Ordinary profit		44,758
Extraordinary income		
Gain on sale of non-current assets	0	
Gain on receipt of share-based remuneration	91	
Settlement income	300	
Other	4	396
Extraordinary losses		
Loss on abandonment of non-current assets	947	
Loss on valuation of shares of subsidiaries and associates	476	
Impairment losses	630	2,054
Profit before income taxes		43,100
Income taxes - current	9,026	
Income taxes - deferred	516	9,542
Profit		33,557